These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36335418)

  • 41. Treatments of refractory eosinophilic lung diseases with biologics.
    Asano K; Suzuki Y; Tanaka J; Kobayashi K; Kamide Y
    Allergol Int; 2023 Jan; 72(1):31-40. PubMed ID: 36333218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factors Affecting the Ability to Discontinue Oral Corticosteroid Use in Patients with EGPA Treated with Anti-Interleukin-5 Therapy.
    Matsuno O
    Int Arch Allergy Immunol; 2024; 185(2):116-123. PubMed ID: 37906985
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Benralizumab: A novel treatment for the cutaneous features of paediatric eosinophilic granulomatosis with polyangiitis (pEGPA).
    Bandla M; Howard M; McNally A; Armstrong D; Simpson I; Mar A
    Australas J Dermatol; 2023 Aug; 64(3):404-407. PubMed ID: 37195732
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting eosinophils: severe asthma and beyond.
    Caminati M; Menzella F; Guidolin L; Senna G
    Drugs Context; 2019; 8():212587. PubMed ID: 31391853
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early add-on administration of mepolizumab and intravenous immunoglobulin effective in treating eosinophilic granulomatosis with polyangiitis.
    Ikeda T; Komatsu T; Yokoyama K; Takahashi K; Kawakami T
    J Dermatol; 2021 Apr; 48(4):529-532. PubMed ID: 33305381
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Eosinophilic granulomatosis with polyangiitis developed during treatment with benralizmab for severe asthma: A case report and literature review.
    Sakabe M; Tobino K; Obata Y; Sogabe S; Uchida K; Murakami Y
    Respirol Case Rep; 2024 Jul; 12(7):e01431. PubMed ID: 38988828
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
    Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
    BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current and emerging biologic therapies targeting eosinophilic disorders.
    Pitlick MM; Li JT; Pongdee T
    World Allergy Organ J; 2022 Aug; 15(8):100676. PubMed ID: 35983569
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities.
    Berti A; Atzeni F; Dagna L; Del Giacco S; Emmi G; Salvarani C; Vaglio A
    Ann Rheum Dis; 2023 Feb; 82(2):164-168. PubMed ID: 36357156
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Updates for the treatment of EGPA.
    Raffray L; Guillevin L
    Presse Med; 2020 Oct; 49(3):104036. PubMed ID: 32652104
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Churg-Strauss syndrome.
    Greco A; Rizzo MI; De Virgilio A; Gallo A; Fusconi M; Ruoppolo G; Altissimi G; De Vincentiis M
    Autoimmun Rev; 2015 Apr; 14(4):341-8. PubMed ID: 25500434
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of Benralizumab and Clinical Course of IgG4 in Eosinophilic Granulomatosis With Polyangiitis.
    Miyata Y; Inoue H; Homma T; Tanaka A; Sagara H
    J Investig Allergol Clin Immunol; 2021 Jul; 31(4):346-348. PubMed ID: 33030432
    [No Abstract]   [Full Text] [Related]  

  • 54. Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.
    Al Efraij K; FitzGerald JM
    Expert Rev Clin Pharmacol; 2018 Jul; 11(7):669-676. PubMed ID: 29972739
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma.
    Menzella F; Ruggiero P; Galeone C; Scelfo C; Bagnasco D; Facciolongo N
    Pulm Pharmacol Ther; 2020 Oct; 64():101966. PubMed ID: 33039666
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
    Hillas G; Fouka E; Papaioannou AI
    Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
    [No Abstract]   [Full Text] [Related]  

  • 57. Adult-onset eosinophilic airway diseases.
    Asano K; Ueki S; Tamari M; Imoto Y; Fujieda S; Taniguchi M
    Allergy; 2020 Dec; 75(12):3087-3099. PubMed ID: 33040364
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
    Cottin V; Bel E; Bottero P; Dalhoff K; Humbert M; Lazor R; Sinico RA; Sivasothy P; Wechsler ME; Groh M; Marchand-Adam S; Khouatra C; Wallaert B; Taillé C; Delaval P; Cadranel J; Bonniaud P; Prévot G; Hirschi S; Gondouin A; Dunogué B; Chatté G; Briault A; Jayne D; Guillevin L; Cordier JF;
    Eur Respir J; 2016 Nov; 48(5):1429-1441. PubMed ID: 27587545
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eosinophilic respiratory disorders and the impact of biologics.
    Bernstein JS; Wechsler ME
    Curr Opin Pulm Med; 2023 May; 29(3):202-208. PubMed ID: 36866734
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eosinophilic Lung Diseases.
    Cottin V
    Immunol Allergy Clin North Am; 2023 May; 43(2):289-322. PubMed ID: 37055090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.